17:00 – 17:10  Opening introduction  
SHAHEENAH DAWOOD, UAE  

17:10 – 19:06  SESSION 1  
CHAIR: MAROUN EL KHOURY, UAE  

17:10 – 17:40  Panel discussion: Rapid fire round of challenging cases  
MODERATOR: SHAHEENAH DAWOOD, UAE  
PANEL: DIAEDDINE AHMAD TRAD, UAE / SUDEEP GUPTA, INDIA  
MOHANAD DIAB, UAE / MASTURA MD YUSOF, MALAYSIA  
AHMED ALI SAADEDIN, KSA / SHONA NAG, INDIA / SAI JONNADA, UAE  

17:42 – 17:57  Snap shot view of 2020: what’s worked and what didn’t  
STEPHEN JOHNSTON, UK  

17:59 – 18:14  Is immunotherapy the standard of care for patients with metastatic TNBC?  
JAVIER CORTES, Spain  

18:16 – 18:31  Optimal utilization of anti HER2 therapy in early stage breast cancer  
SHAHEENAH DAWOOD, UAE  

18:33 – 18:48  Which anti HER2 therapy and when in metastatic breast cancer?  
ZULFAQQAR JAFFAR ALI, UAE  

18:50 – 19:10  Lift HER care: an evolution in the clinic Supported by Roche  
JAWAHER ANSARI, UAE  

19:10 – 19:20  Break and Q&A session  

19:20 – 20:40  SESSION 2  
CHAIR: DIAEDDINE AHMAD TRAD, UAE  

19:20 – 19:40  HR+, Her2- MBC patient with Visceral disease, Supported by Lilly  
ANWAR AL NOURI, Kuwait  

19:42 – 20:02  Endocrine therapy in metastatic breast cancer: sequencing choices available  
MOHSEN MOKHTAR, Egypt  

20:04 – 20:34  Breast cancer molecular tumor board:  
Fitting liquid and tissue profiling into the management of patients with breast cancer  
MODERATOR: GREGORY VIDAL, USA  
PANEL: SHONA NAG, INDIA / OMAL KHAIR, KSA / SUDEEP GUPTA, INDIA  
NOURI BENNINI, UAE / BASSIM AL BAHRANI, OMAN  
MOHAMMED SAAED AHMED, UAE  

20:35 – 20:40  Closing Note